{"id":5641,"date":"2024-06-13T16:30:39","date_gmt":"2024-06-13T16:30:39","guid":{"rendered":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/?p=5641"},"modified":"2024-06-14T01:08:20","modified_gmt":"2024-06-14T01:08:20","slug":"quintana","status":"publish","type":"post","link":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/quintana\/","title":{"rendered":"Melanie Quintana, PhD"},"content":{"rendered":"<p><img decoding=\"async\" class=\"lazyload alignnone size-full wp-image-5642\" src=\"http:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Melanie-Quintana.png\" data-orig-src=\"http:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Melanie-Quintana.png\" alt=\"\" width=\"300\" height=\"300\" srcset=\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27300%27%20height%3D%27300%27%20viewBox%3D%270%200%20300%20300%27%3E%3Crect%20width%3D%27300%27%20height%3D%27300%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" data-srcset=\"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Melanie-Quintana-66x66.png 66w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Melanie-Quintana-150x150.png 150w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Melanie-Quintana-200x200.png 200w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Melanie-Quintana.png 300w\" data-sizes=\"auto\" data-orig-sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>Melanie Quintana is a Director and Senior Statistical Scientist at Berry Consultants, where she specializes in designing Bayesian adaptive clinical trials across a wide range of therapeutic areas. \u00a0Her work includes numerous examples in designing platform trials and clinical trials in rare and progressive disease with a focus on developing models of disease progression to design better and more powerful clinical trials. \u00a0Before joining Berry Consultants, she earned her Ph.D. in Statistics from Duke University and went on to pursue a Postdoc in Biostatistics at The University of Southern California. \u00a0While at Duke and USC, she worked closely with collaborators within multiple large studies and consortiums around the nation to develop and implement analytical strategies to assess genetic risk factors for various complex diseases. These collaborations sparked and continue to fuel her interests in developing Bayesian approaches for complex clinical questions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Melanie Quintana is a Director and Senior Statistical Scientist at Berry Consultants, where she specializes in designing Bayesian adaptive clinical trials across a wide range of therapeutic areas. \u00a0Her work includes numerous examples in designing platform trials and clinical trials in rare and progressive disease with a focus on developing models of disease progression to [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5642,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":["post-5641","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-creative"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/comments?post=5641"}],"version-history":[{"count":1,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5641\/revisions"}],"predecessor-version":[{"id":5643,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5641\/revisions\/5643"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/media\/5642"}],"wp:attachment":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/media?parent=5641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/categories?post=5641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/tags?post=5641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}